Бета-блокаторы и артериальная гипертензия: существуют ли непреодолимые ограничения?


В.В. Фомин, А.А. Свистунов

Обсуждаются современные позиции бета-адреноблокаторов в лечении артериальной гипертензии. Проанализирован опыт клинических исследований, в которых применяли бисопролол.

Литература


1. Kjeldsen SE, Erdine S, Farsang S, et al.; WHO/ISH Hypertension Guidelines subcommittee. J Hypertens. 2002; 20(1): 153–55.
2. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first-choice in the treatment of primary hypertension? A metaanalysis. Lancet 2005; 366: 1545–53.
3. Lindholm LH, Carlberg B, Samuelsson O. Beta blockers in primary hypertension: do age and type of beta blocker matter? J. Hypertens. 2006; 24(11): 2143–45.
4. Dahlof B, Sever P. Poulter NR, et al., ASCOT Investigators. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
5. The CAFЕ Investigators. Differential impact of blood-pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFЕ) study. Circulation. 2006 113(9): 1213–25.
6. Sever P. New hypertension gulidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J. Renin Angiotensin Aldosterone Syst. 2006; 7(2): 61 – 63
7. Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics,potassium and the development of diabetes. A quantative review. Hypertension 2006; 48: 219–24.
8. Комитет экспертов РМОАГ/ВНОК.Диагностика и лечение артериальной гипертензии. Рекомендации РМОАГ/ВНОК. Системные гипертензии 2010; 3: 5–26.
9. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994; 90(4): 1765–73.
10. Eichhrorn EJ, Hjalmarson A. Beta-blocker treatment for chronic heart failure. The frog prince. Circulation. 1994; 90(4): 2153–56.
11. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353(9146): 9–13.
12. Castagno D, Jhund PS, McMurray JJ et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail. 2010; 12(6): 607–16.
13. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail. 2001; 3(4): 469–79.
14. Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies-CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J. 2002; 143(2): 301–07.
15. Willenheimer R, van Veldhuisen DJ, Silke B, et al.; CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril,
as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005; 112(16): 2426–35.
16. Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, Follath F, Goulder M, Willenheimer R; CIBISIII investigators. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail. 2011; 13(7):765–72.
17. Krum H, Van Veldhuisen DJ, Funck-Brentano C, et al.; on behalf of the CIBIS III Investigators. Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial. Cardiovasc Ther. 2010 Jun 1. doi: 10.1111/j.1755–5922.2010.00185.x. [Epub ahead of print].
18. Simon T, Mary-Krause M, Funck-Brentano C, Lechat P. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). Eur Heart J. 2003; 24(6): 552–59.
19. Nishio M, Sakata Y, Mano T et al. Beneficial effects of bisoprolol on the survival of hypertensive
2008; 10(5):446–53.
20. Ilgenli TF, Kilicaslan F, Kirilmaz A, Uzun M. Bisoprolol improves echocardiographic parameters of left ventricular diastolic function in patients with systemic hypertension. Cardiology. 2006; 106(3): 127–31.
21. Lin ZP, Dong M, Liu J. Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: a randomized double-blinded trial. Eur Rev Med Pharmacol Sci. 2013; 17(6):794–801.
22. Channaraya V, Marya RK, Somasundaram M, Mitra D, Tibrewala KD; BRIGHT investigators.Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study. BMJ Open.
2012; 2(3). pii: e000683.
23. Satoh M, Obara T, Ikeda U, et al. Hypotensive and heart rate-lowering effects of low-dose bisoprolol determined based on self-measured blood pressure at home. Clin Exp Hypertens. 2012; 34(4): 284–89.
24. Daskalopoulou SS, Khan NA, Quinn RR, et al.; Canadian Hypertension Education Program. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2012; 28(3): 270–87.


Похожие статьи


Бионика Медиа